American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Latest News

Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial

by admin April 18, 2025
April 18, 2025
Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial

Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing in the fast-growing market for weight loss and diabetes treatments.

The results, announced Thursday, show the pill could offer a compelling, needle-free alternative to popular injections, potentially reshaping how millions of people manage chronic conditions.

Shares of Eli Lilly rose as much as 11% in premarket trading on Thursday as investors welcomed the results, which put the company a step ahead of rivals such as Novo Nordisk in developing an oral version of the lucrative GLP-1 class of drugs.

The US pharmaceutical giant reported that orforglipron helped patients with Type 2 diabetes achieve both weight loss and improved blood sugar control.

The trial, one of seven late-stage studies underway, also found the pill’s side effect profile to be largely manageable and in line with what is observed in injectable drugs already on the market.

A promising alternative to injections

At its highest dose, orforglipron led to an average weight loss of 7.9% — roughly 16 pounds — over 40 weeks.

Notably, patients had not plateaued in their weight loss by the end of the study, suggesting that longer treatment may yield further results.

This development is significant for patients seeking a more convenient alternative to injectables like Wegovy and Ozempic.

Pills are easier to manufacture and distribute at scale, which could help alleviate the persistent supply shortages that have plagued the market for injectable GLP-1 drugs.

CEO David Ricks emphasized the potential impact in a company statement:

We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control, and weight loss. We look forward to additional data readouts later this year.”

Safety is in line with expectations

Side effects were mostly mild to moderate, with gastrointestinal symptoms such as nausea, vomiting, and diarrhea reported.

Around 8% of patients on the highest dose discontinued treatment due to side effects, which analysts say is within an acceptable range.

In comparison, injectable versions of the drug class tend to have similar or slightly lower discontinuation rates, though they are administered weekly rather than daily.

Analysts had expected discontinuation rates around 9%, indicating that the results came in close to forecast.

TD Cowen and other investment firms had anticipated that side effects could be marginally worse with a daily oral pill.

Mixed results on diabetes metric

Despite positive signs, orforglipron fell short of some analyst expectations when it came to lowering hemoglobin A1c, a key diabetes marker.

The pill reduced blood sugar levels by 1.3% to 1.6% across doses after 40 weeks, from a starting level of 8%.

This compares with reductions as high as 2.1% seen in some patients using Novo Nordisk’s injection Ozempic.

The result remains clinically meaningful, but the gap could influence prescribing patterns if physicians view injections as more effective for glucose control.

Still, the pill’s ease of use may be enough to offset that in patients prioritizing convenience.

Looking ahead to regulatory filings

Eli Lilly plans to file for regulatory approval for orforglipron in obesity by the end of 2025, with a diabetes filing expected in 2026.

The company is currently conducting five trials in diabetes and two in obesity, with more data expected later this year.

The pill is not a peptide-based drug, meaning it is absorbed more easily by the body and doesn’t require food restrictions, unlike Novo Nordisk’s diabetes pill Rybelsus.

This could make it more appealing to a broader patient population.

Analysts forecast the GLP-1 market could exceed $150 billion annually by the early 2030s, with oral drugs accounting for up to $50 billion.

Eli Lilly, already a leader with injectable drugs like Mounjaro, may solidify its dominance if orforglipron gains approval.

With its lead over competitors including AstraZeneca, Roche, Structure Therapeutics, and Viking Therapeutics, Eli Lilly is positioning itself to be the first to offer a widely available oral GLP-1 therapy — and reshape the landscape of chronic disease management.

The post Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
ECB cuts rates by 25 bps as inflation eases, but warns trade tensions cloud growth outlook
next post
Czech Republic ends reliance on Russian oil after 60 years

Related Posts

Asian stocks rise as US Fed holds rates...

January 30, 2025

Nipah virus death puts health officials on alert...

July 22, 2024

K-pop star ends relationship weeks after it sparked...

April 4, 2024

How rock icon Jimi Hendrix inspired one of...

July 31, 2024

Gold prices steady as Fed rate cut expectations...

December 17, 2024

21 people die as school building collapses in Nigeria when students...

July 14, 2024

Bangladesh has erupted over jobs reserved for the...

July 19, 2024

This remote, mystical forest has been protected for...

August 9, 2024

German elections countdown: the uncomfortable truth about Germany’s...

February 22, 2025

UK’s credit and housing markets signal economic strains...

January 4, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Analysis: oil market braces for Mideast volatility, but prices unlikely to top $80/barrel

      June 16, 2025
    • Interview: Strategic location gives Brazil Potash cost advantage in domestic fertiliser market, says CEO Matt Simpson

      June 1, 2025
    • Canada’s Q1 GDP expands by 2.2%, driven by exports spike ahead of potential US tariffs

      June 1, 2025
    • President Trump to host farewell for Elon Musk as DOGE leader steps away

      June 1, 2025
    • UK’s digital banks face divergent fortunes: Starling stumbles, Monzo and Revolut soars

      June 1, 2025

    Categories

    • Business (3,155)
    • Investing (2,512)
    • Latest News (1,995)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved